DATA SHEET LANVIS Medsafe（数据表LANVISMedsafe）.pdfVIP

DATA SHEET LANVIS Thioguanine Tablets 40mg Qualitative and Quantitative Composition White to off-white tablet, round, biconvex scored and debossed with ‘T40’ on one side and plain on the other side. Pharmaceutical form Tablets Clinical particulars Therapeutic Indications LANVIS is indicated primarily for the treatment of acute leukaemias especially:- acute myelogenous leukaemia acute lymphoblastic leukaemia LANVIS is also used in the treatment of chronic granulocytic leukaemia. Posology and Method of Administration The exact dose and duration of administration will depend on the nature and dosage of other cytotoxic drugs given in conjunction with LANVIS. LANVIS is variably absorbed following oral administration and plasma drug levels may be reduced following emesis or intake of food. Thioguanine can be used at any stage prior to maintenance therapy in short term cycles e.g. induction, consolidation, intensification. However, it is not recommended for use during maintenance therapy or similar long term continuous treatments due to the high risk of liver toxicity (see Special Warnings and Special Precautions for Use and Undesirable Effects). 1 Adults:-For adults, the usual dosage of LANVIS is between 60 and 200mg/m2 body surface area per day. Children:- For children, similar dosages to those used in adults, with appropriate correction for body surface area, have been used. Elderly Patients:- There are no specific dosage recommendations in elderly patients. (See Dosage in renal or hepatic impairment). LANVIS has been used in various combination chemotherapy schedules in elderly patients with acute leukaemia at equivalent dosages to those used in younger patients. Dosage in renal or hepatic impairment:- Consideration should be given to reducing the dosage in patients with impaired hepatic or renal function. Contraindications Hypersensitivity